205 related articles for article (PubMed ID: 23660011)
1. STAT5A/B gene locus undergoes amplification during human prostate cancer progression.
Haddad BR; Gu L; Mirtti T; Dagvadorj A; Vogiatzi P; Hoang DT; Bajaj R; Leiby B; Ellsworth E; Blackmon S; Ruiz C; Curtis M; Fortina P; Ertel A; Liu C; Rui H; Visakorpi T; Bubendorf L; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Nevalainen MT
Am J Pathol; 2013 Jun; 182(6):2264-75. PubMed ID: 23660011
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.
Mirtti T; Leiby BE; Abdulghani J; Aaltonen E; Pavela M; Mamtani A; Alanen K; Egevad L; Granfors T; Josefsson A; Stattin P; Bergh A; Nevalainen MT
Hum Pathol; 2013 Mar; 44(3):310-9. PubMed ID: 23026195
[TBL] [Abstract][Full Text] [Related]
3. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.
Dagvadorj A; Kirken RA; Leiby B; Karras J; Nevalainen MT
Clin Cancer Res; 2008 Mar; 14(5):1317-24. PubMed ID: 18316550
[TBL] [Abstract][Full Text] [Related]
4. N-terminal truncation of Stat5a/b circumvents PIAS3-mediated transcriptional inhibition of Stat5 in prostate cancer cells.
Dagvadorj A; Tan SH; Liao Z; Xie J; Nurmi M; Alanen K; Rui H; Mirtti T; Nevalainen MT
Int J Biochem Cell Biol; 2010 Dec; 42(12):2037-46. PubMed ID: 20854925
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
6. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
7. STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.
Maranto C; Udhane V; Hoang DT; Gu L; Alexeev V; Malas K; Cardenas K; Brody JR; Rodeck U; Bergom C; Iczkowski KA; Jacobsohn K; See W; Schmitt SM; Nevalainen MT
Clin Cancer Res; 2018 Apr; 24(8):1917-1931. PubMed ID: 29483142
[No Abstract] [Full Text] [Related]
8. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.
Tan SH; Dagvadorj A; Shen F; Gu L; Liao Z; Abdulghani J; Zhang Y; Gelmann EP; Zellweger T; Culig Z; Visakorpi T; Bubendorf L; Kirken RA; Karras J; Nevalainen MT
Cancer Res; 2008 Jan; 68(1):236-48. PubMed ID: 18172316
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth.
Gu L; Dagvadorj A; Lutz J; Leiby B; Bonuccelli G; Lisanti MP; Addya S; Fortina P; Dasgupta A; Hyslop T; Bubendorf L; Nevalainen MT
Am J Pathol; 2010 Apr; 176(4):1959-72. PubMed ID: 20167868
[TBL] [Abstract][Full Text] [Related]
10. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.
Talati PG; Gu L; Ellsworth EM; Girondo MA; Trerotola M; Hoang DT; Leiby B; Dagvadorj A; McCue PA; Lallas CD; Trabulsi EJ; Gomella L; Aplin AE; Languino L; Fatatis A; Rui H; Nevalainen MT
Am J Pathol; 2015 Sep; 185(9):2505-22. PubMed ID: 26362718
[TBL] [Abstract][Full Text] [Related]
11. Positive STAT5 Protein and Locus Amplification Status Predicts Recurrence after Radical Prostatectomy to Assist Clinical Precision Management of Prostate Cancer.
Haddad BR; Erickson A; Udhane V; LaViolette PS; Rone JD; Kallajoki MA; See WA; Rannikko A; Mirtti T; Nevalainen MT
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1642-1651. PubMed ID: 31292140
[TBL] [Abstract][Full Text] [Related]
12. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism.
Tran TH; Utama FE; Lin J; Yang N; Sjolund AB; Ryder A; Johnson KJ; Neilson LM; Liu C; Brill KL; Rosenberg AL; Witkiewicz AK; Rui H
Cancer Res; 2010 Feb; 70(4):1711-21. PubMed ID: 20124477
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract][Full Text] [Related]
14. Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer.
Koptyra M; Gupta S; Talati P; Nevalainen MT
Int J Biochem Cell Biol; 2011 Oct; 43(10):1417-21. PubMed ID: 21704724
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.
Liao Z; Gu L; Vergalli J; Mariani SA; De Dominici M; Lokareddy RK; Dagvadorj A; Purushottamachar P; McCue PA; Trabulsi E; Lallas CD; Gupta S; Ellsworth E; Blackmon S; Ertel A; Fortina P; Leiby B; Xia G; Rui H; Hoang DT; Gomella LG; Cingolani G; Njar V; Pattabiraman N; Calabretta B; Nevalainen MT
Mol Cancer Ther; 2015 Aug; 14(8):1777-93. PubMed ID: 26026053
[TBL] [Abstract][Full Text] [Related]
16. Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
Gu L; Zhu XH; Visakorpi T; Alanen K; Mirtti T; Edmonston TB; Nevalainen MT
Anal Cell Pathol (Amst); 2010; 33(2):55-9. PubMed ID: 20966544
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
Hoang DT; Gu L; Liao Z; Shen F; Talati PG; Koptyra M; Tan SH; Ellsworth E; Gupta S; Montie H; Dagvadorj A; Savolainen S; Leiby B; Mirtti T; Merry DE; Nevalainen MT
Mol Cancer Ther; 2015 Mar; 14(3):713-26. PubMed ID: 25552366
[TBL] [Abstract][Full Text] [Related]
18. Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
Erb HHH; Bodenbender J; Handle F; Diehl T; Donix L; Tsaur I; Gleave M; Haferkamp A; Huber J; Fuessel S; Juengel E; Culig Z; Thomas C
PLoS One; 2020; 15(8):e0237248. PubMed ID: 32790723
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
Medler TR; Craig JM; Fiorillo AA; Feeney YB; Harrell JC; Clevenger CV
Mol Cancer Res; 2016 Oct; 14(10):994-1008. PubMed ID: 27358110
[TBL] [Abstract][Full Text] [Related]
20. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.
Gu L; Vogiatzi P; Puhr M; Dagvadorj A; Lutz J; Ryder A; Addya S; Fortina P; Cooper C; Leiby B; Dasgupta A; Hyslop T; Bubendorf L; Alanen K; Mirtti T; Nevalainen MT
Endocr Relat Cancer; 2010 Jun; 17(2):481-93. PubMed ID: 20233708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
